Literature DB >> 7506655

Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.

P Mikus1, T Urano, P Liljeström, T Ny.   

Abstract

Plasminogen-activator inhibitor type 2 (PAI-2) is a specific inhibitor of plasminogen activators (PA) that exists in an intracellular, low-molecular-mass form and a secreted, high-molecular-mass form that varies with respect to glycosylation. Here we have developed expression systems for both forms of PAI-2 and biochemically characterised the purified proteins. In order to obtain efficient secretion, we constructed an artificial signal sequence and fused it to the coding region of PAI-2. With this construct, more than 90% of PAI-2 was secreted as a glycosylated, 60-kDa molecular-mass form, but the level of expression was low and unstable. To obtain higher expression of secreted PAI-2, a novel expression vector based on the Semliki-forest-virus replicon was used. Secreted PAI-2 was purified to homogeneity and N-terminal sequence analysis showed that the artificial signal peptide was correctly removed. The intracellular, non-glycosylated form of PAI-2 was expressed in Escherichia coli and purified to homogeneity. Both the secreted and the intracellular forms of PAI-2 were found to inhibit plasminogen activators by forming SDS-resistant complexes and the second-order rate constants were similar for both forms, ranging over 2.4-2.7 x 10(6) M-1s-1 for urokinase-type PA, 2.5-2.7 x 10(5) M-1s-1 for two-chain tissue-type PA and 0.8-1.2 x 10(4) M-1s-1 for single-chain tissue-type PA. None of the purified PAI-2 forms bound to vitronectin. Circular-dichroism spectral analysis revealed that PAI-2 has a CD spectrum that resembles ovalbumin more than PA-inhibitor type 1, confirming the greater similarity between these two members of the serine-protease inhibitor family. Similar to what has been described for the Z-form of alpha 1-antitrypsin, purified PAI-2 was found to spontaneously form polymers during incubation at room temperature. Attempts to convert PAI-2 to a stable locked conformation resembling the conformation of latent PAI-1 by treatment with diluted guanidinium chloride were unsuccessful. Instead, this treatment enhanced the formation of PAI-2 polymers, possibly by the loop-sheet polymerisation mechanism described for alpha 1-antitrypsin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506655     DOI: 10.1111/j.1432-1033.1993.tb18467.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

1.  Recombinant protein production using the Semliki Forest Virus expression system.

Authors:  H D Blasey; K Lundström; S Tate; A R Bernard
Journal:  Cytotechnology       Date:  1997-05       Impact factor: 2.058

2.  Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy.

Authors:  H Koloczek; A Banbula; G S Salvesen; J Potempa
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

3.  Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins.

Authors:  W S Chang; J Whisstock; P C Hopkins; A M Lesk; R W Carrell; M R Wardell
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

4.  A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization.

Authors:  Malgorzata Wilczynska; Sergei Lobov; Per-Ingvar Ohlsson; Tor Ny
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

5.  Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.

Authors:  Blake J Cochran; David R Croucher; Sergei Lobov; Darren N Saunders; Marie Ranson
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

6.  Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.

Authors:  S A Siefert; C Chabasse; S Mukhopadhyay; M H Hoofnagle; D K Strickland; R Sarkar; T M Antalis
Journal:  J Thromb Haemost       Date:  2014-09-30       Impact factor: 5.824

Review 7.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

8.  A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy.

Authors:  T Miyata; M Nangaku; D Suzuki; R Inagi; K Uragami; H Sakai; K Okubo; K Kurokawa
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  The human serpin proteinase inhibitor-9 self-associates at physiological temperatures.

Authors:  Lauren N Benning; James C Whisstock; Jiuru Sun; Phillip I Bird; Stephen P Bottomley
Journal:  Protein Sci       Date:  2004-07       Impact factor: 6.725

10.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.